The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCO 2024 | Agents currently in clinical trial for the treatment of PV: rusfertide, sapablursen, and bomedemstat
Ciro Rinaldi, MD, PhD, Lincoln County Hospital, Lincoln, UK, discusses recent advancements in the treatment of polycythemia vera (PV). This includes hepcidin mimetics rusfertide and sapablursen, and the lysine-specific demethylase 1 (LSD1) inhibitor bomedemstat. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
I think for quite a few years we haven’t had a new drug in polycythemia vera. And in the last 4 or 5 years we probably have three interesting drugs. Two of them are part of what they call hepcidin mimetic that can increase or replace hepcidin in the iron metabolism. And that could help in reducing the phlebotomy in patients with polycythemia vera. I’m talking about rusfertide and I’m talking about the second sapablursen...
I think for quite a few years we haven’t had a new drug in polycythemia vera. And in the last 4 or 5 years we probably have three interesting drugs. Two of them are part of what they call hepcidin mimetic that can increase or replace hepcidin in the iron metabolism. And that could help in reducing the phlebotomy in patients with polycythemia vera. I’m talking about rusfertide and I’m talking about the second sapablursen. They act in a different way. One is a direct mimetic of hepcidin. The second one is an indirect mimetic, so we increase the production of endogenous hepcidin, reverting the absorption of iron into bone marrow, reducing the need of lobotomy. And obviously bomedemstat is another interesting one, which we discussed already, which could potentially reduce the activity of the polycythemia clone. And so those drugs are either in phase two and phase three trials. And it would be very interesting to see results in the next few months.
Read more...
